If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIlika Plc Regulatory News (IKA)

Share Price Information for Ilika Plc (IKA)

Share Price is delayed by 15 minutes
Get Live Data
28.50    -0.80 (-2.76%)
Bid:
28.00
Ask:
29.00
Spread: 1.00 (3.571%)
Market Cap: £50.99m
IKA Live PriceLast checked at - London Stock Exchange

Intraday Ilika Plc Share Chart

Goliath P1 Cells Validated by Customer Testing

1 May 2025 07:00

RNS Number : 8702G
Ilika plc
01 May 2025
 

Ilika plc

("Ilika", the "Group", or the "Company")

 

Goliath P1 Cells Validated by Customer Testing

 

Ilika (AIM: IKA), an independent global expert in solid-state battery technology, announces that it has received confirmation from OEM and Tier 1 testing partners that its P1 Goliath prototypes perform to specification.

 

Further to its RNS of May 2024 announcing commencement of testing of P1 prototype cells on behalf of, and subsequently by, commercial partners, Ilika confirms that the suite of tests including cell formation protocol, measurement of energy capacity, charge rate, power delivery capability and accelerated cyclability have confirmed the specification of its P1 cells. Furthermore, the tests demonstrated good reproducibility across the batch and delivered the expected electrochemical signature.

 

The tests were carried out under commercial agreements with confidentiality provisions designed to protect proprietary duty cycle protocols owned by the OEMs and Tier 1 companies. The test protocols used are representative of those used to evaluate batteries for electric vehicles and, while the protocols vary from one partner to another, the results have been consistent, and they are globally relevant.

 

The Head of Battery Development at an UK-based electrification Tier 1 supplying global OEMs, stated, "We can confirm that we have completed testing of Ilika's P1 prototypes and they perform to specification, putting them in the cohort of leading solid-state batteries we have tested. We look forward to evaluating further prototypes as Ilika progresses through its roadmap."

 

Graeme Purdy, Ilika CEO, stated, "Customer validation of our Goliath roadmap is of primary importance to us to ensure that we are progressing towards a minimum viable product that meets or exceeds customer expectations. Clearly, this set of validations increases our confidence in the attractiveness of our roadmap. We will continue to engage with a portfolio of potential manufacturing partners to minimise commercialisation risk."

 

In parallel with the validation programmes carried out on its P1s, Ilika has continued to develop its batteries as outlined in its 2024 annual report. In October 2024, Ilika announced compelling safety test data validated by the Faraday Institution's Safebatt programme. Ilika is currently conducting in-house testing of larger 10Ah cells associated with its materials design freeze before releasing its 10Ah (P1.5) prototypes in H2 CY25. Ilika's near-term roadmap extends through to 50Ah minimum viable product (MVP), with the first release expected at the end CY25. Ilika's Goliath MVP, or P2 prototypes, will underpin licensing opportunities.

 

ENDS

 

--

Enquiries:

 

Ilika Plc Graeme Purdy, Chief Executive

Jason Stewart, Chief Financial Officer

 

www.ilika.com

Via FTI Consulting

 

Cavendish Capital Markets Limited (Nomad and Broker) Peter Lynch

Neil McDonald

 

+44 (0)131 220 9772

+44 (0)131 220 9771

 

FTI Consulting (Comms Advisors)

Ben Brewerton

Elizabeth Adams

Dwight Burden

ilika@fticonsulting.com

 

 

About Ilika plc - https://www.ilika.com

 

Ilika is a global expert in the development of solid state battery technology for electric vehicles, medical devices and consumer appliances. The Company's pioneering next-generation technologies aim to provide scalable, affordable alternatives to conventional batteries, to industries which need to incorporate a smaller, lighter, and safer power source in their products.

 

The Company has two product lines. Its Stereax batteries are designed for powering miniature medical implants, industrial wireless sensors and Internet of Things (IoT) applications and the Goliath large format batteries designed for EV cars and cordless appliances.

 

Through its licensing business model, Ilika supplies its IP portfolio to both OEMs and manufacturing partners in exchange for a license fee and future royalties.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFBLFXEZLZBBF
Date   Source Headline
30th Apr 201210:27 amRNSDirector's Dealings
30th Apr 201210:22 amRNSTotal Voting Rights
25th Apr 20122:02 pmRNSHolding(s) in Company
23rd Apr 20122:44 pmRNSHolding(s) in Company
23rd Apr 20128:01 amRNSDirector/PDMR Shareholding
20th Apr 201212:49 pmRNSGeneral Meeting Results
4th Apr 201212:26 pmRNSPosting of circular
4th Apr 20127:00 amRNSPlacing and Subscription
13th Mar 20127:00 amRNSContract Renewals and Trading Update
2nd Feb 20127:00 amRNSJoint Development agreement with Energizer
10th Jan 20127:00 amRNSHalf Yearly Report
9th Jan 20127:00 amRNSNew contract with Toshiba
6th Dec 20117:00 amRNSAltrika grant award and new JDP
28th Nov 20117:00 amRNSSolid State Battery Development
16th Nov 20117:00 amRNSTrading Update
29th Sep 20118:21 amRNSFirst US electronics contract / Expansion in Asia
13th Sep 20115:06 pmRNSResult of AGM
2nd Aug 20117:00 amRNSPosting of annual report
14th Jul 20117:00 amRNSFull Year Results
4th May 20117:00 amRNSTrading Update
18th Apr 20117:00 amRNSCarbon Trust Grant / New Customer Contract
4th Mar 20118:00 amRNSRenewal of Contracts
24th Feb 20112:56 pmRNSNotification of Interest
23rd Feb 201112:16 pmRNSNotification of Interest
19th Jan 20113:00 pmRNSDISTRIBUTION OF INTERIM ACCOUNTS FOR 2010
24th Nov 20107:00 amRNSInterim Results
29th Oct 20107:00 amRNSIlika awarded Carbon Trust R&D Grant
21st Oct 20107:00 amRNSAgreement with Ministry of Defence agency
21st Oct 20107:00 amRNSAgreement with Ministry of Defence agency
20th Oct 20104:35 pmRNSAnnual Financial Report
20th Oct 20104:35 pmRNSAnnual Financial Report
8th Oct 201010:30 amRNSInternational Business Development Appointments
8th Sep 20107:00 amRNSRevenue Update and Contract Renewal
18th Aug 20104:13 pmRNSNotification of Interest
17th Aug 20107:00 amRNSTotal Voting Rights
5th Aug 20104:05 pmRNSHolding(s) in Company
28th Jul 20107:00 amRNSUK Government Grant for Skin Wound Treatment
15th Jul 20107:00 amRNSFuel Cell Materials Joint Development Project
15th Jul 20107:00 amRNSFinal Results
30th Jun 20107:00 amRNSDevelopment Project
16th Jun 20107:00 amRNSFuel cell catalyst scale-up agreement
10th Jun 201012:39 pmRNSInspection, Regulatory Authority for Skin Products
9th Jun 20109:25 amRNSIlika partners to develop business in China
2nd Jun 20104:25 pmRNSExercise of Options
14th May 20105:16 pmRNSGrant of Options
14th May 20105:16 pmRNSGrant of Options
14th May 20108:02 amRNSAdmission to AIM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.